Longevity Nerd

APOE genotype is fixed at birth, yet Alzheimer's appears decades later. We asked whether the fixed APOE ε2/ε4 plasma-protein substrate (Lu 2026) interacts with the age-emergent proteome — three proteomic waves (Lehallier 2019) and many organ and cell-type aging clocks (Ding 2026, Oh 2023) — by testing protein-network coupling across five interactomes and two states (plasma and brain), against degree-matched nulls. Network-wise, the two programs are largely segregated across most aging and aging-related changes and both alleles — especially ε2. One moderate overlap sits at ε4 × later-life aging (the ~78-year wave), carried by a lipoprotein/ECM arm (APOM, FBLN1 → CLU, APOL1, FN1), an inflammatory arm (IL6ST, KITLG, RGMA → IL6 / STAT3, KIT) and a neuronal arm (NEGR1, NPTX2, NRXN1, GFRA2). Independent human genetics give these proteins support for causality inference — CLU in Alzheimer's, FN1 in coronary artery disease — and both are potential drug targets, with CLU-raising compounds already showing preclinical Alzheimer's efficacy (Cohn 2025). Built and stress-tested two ways with Claude Science: one chat end-to-end, and a multi-chats system passing results through shared artifacts.